Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. A platform technology based on the AβCC peptides™ provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the disease-driving oligomers, currently under validation as an accompanying diagnostic.